The plethora of targetable variants among non-small cell lung cancers is on the rise, making it one of the most important cancer types in the context of precision oncology. Recently, the MET exon14 skipping mutation has emerged as a novel therapeutic target. This mutation results from somatic alterations at the splice junction of exon 14 of the MET gene, leading to constitutive activation of downstream signaling pathways. The approval of targeted therapy for this variation makes it a compelling need to use appropriate testing systems for detection. Utilising a robust next-generation sequencing platform, we have identified this mutation in 5.3% of cases in our cohort. In the absence of information on MET exon 14 skipping from India, this case series will throw some light on this variation in our subcontinent and highlights the fact that the real-world effectiveness of MET inhibitors like Tepotinib and Capmantinib might be lower than expected.
Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
